Last weekend, our colleagues in Boulder, CO, participated in the 14th Annual B Strong Ride, celebrating cancer survivorship and helping fund a complete year of care at Boulder Community Health Center for Integrative Care. Congratulations to the Editas team and all the B Strong participants! #InsideEditas
Editas Medicine
Biotechnology Research
Cambridge, Massachusetts 45,277 followers
What If You Could Repair Broken Genes?
Über uns
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
- Website
-
http://www.editasmedicine.com
External link for Editas Medicine
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- Cambridge, Massachusetts
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2013
- Spezialitäten
- Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
Standorte
-
Primäre
11 Hurley St
Cambridge, Massachusetts 02141, US
-
4909 Nautilus Ct N
Suite 208/211
Boulder, Colorado 80301, US
Employees at Editas Medicine
Aktualisierungen
-
Every day at Editas, our goal is to develop medicines for people living with serious diseases. For us, the patient and caregiver are – and must be – at the center of everything we do. Connecting with people like Stephanie keeps us informed of the patient community’s greatest priorities as we develop transformative medicines. Learn more about how we’re pioneering the possible: https://bit.ly/3Z1gVYn #community #patientadvocacy #transformativemedicines
-
Earlier today, we reported business highlights and financial results for the second quarter 2024. Learn more: https://bit.ly/3LVJAWY #geneediting #biotechnology
-
Today we announced business updates and financial results for the second quarter 2024. Read the press release for details: https://bit.ly/3LVJAWY #geneediting #biotechnology
-
Editas Medicine will host a conference call and webcast tomorrow, August 7, at 8:00 a.m. ET to discuss results for the second quarter 2024 and to provide business updates. Read the press release for details: https://bit.ly/3SxsMsR #geneediting #biotechnology
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update | Editas Medicine
ir.editasmedicine.com
-
#News: Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update. Read the press release for details: https://bit.ly/3SxsMsR #geneediting #biotechnology
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update | Editas Medicine
ir.editasmedicine.com
-
Community is in our DNA. We have gathered with patients, caregivers, and others to support the Sickle Cell community at the 11th Annual Sickle Cell Warriors Convention. #SickleCellAwareness #SickleCellAdvocacy #WarriorsConvention2024
-
Over the weekend, Editas employees along with others, biked together in The Prouty, an important event to raise funds and awareness for life-saving research and critical patient and family support services at Dartmouth Cancer Center. We are so proud of our team and congratulate them on this incredible achievement in support of a great cause! #InsideEditas #cancerresearch
-
Did you know that more than 90% of rare disease patients have no FDA-approved products for their condition. We’re at the Alliance for Regenerative Medicine for Regenerative Medicine #CGFlyIn24 advocating for supporting innovation and expanding access for patients to cell and gene therapies. #GeneTherapy #CellandGeneTherapy #RareDiseases
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Eigenkapital nach dem IPOUS$ 125.0M